S3 Table. Baseline characteristics of stage II/III patients in the unmatched and matched samples

	Unmatched sample				Matched sample[a)]		
	No adjuvant chemotheraphy (n=182)	Adjuvant chemotheraphy (n=128)	p-value[b)]	SMD[c)]	No adjuvant chemotheraphy (n=123)	Adjuvant chemotheraphy (n=123)	SMD[c)]
Age (yr)	62.17±10.46	60.38±8.68	0.112	0.187	60.95±10.27	60.63±8.57	0.034
Sex							
Male	107 (58.8)	83 (64.8)			77 (62.6)	78 (63.4)	
Female	75 (41.2)	45 (35.2)	0.281	0.125	46 (37.4)	45 (36.6)	0.017
Stage							
II	70 (38.5)	44 (34.4)	0.463	0.085	41 (33.3)	43 (35.0)	0.034
III	112 (61.5)	84 (65.6)			82 (66.7)	80 (65.0)	
LVI							
Absent	85 (46.7)	41 (32.0)	0.010	0.304	40 (32.5)	41 (33.3)	0.017
Present	97 (53.3)	87 (68.0)			83 (67.5)	82 (66.7)	
PNI							
Absent	118 (64.8)	76 (59.4)	0.328	0.113	75 (61.0)	74 (60.2)	0.017
Present	64 (35.2)	52 (40.6)			48 (39.0)	49 (39.8)	
Histology							
W/D	29 (15.9)	12 (9.4)	0.224	0.204	10 (8.1)	12 (9.8)	0.059
M/D	132 (72.5)	98 (76.6)			94 (76.4)	93 (75.6)	
P/D	21 (11.5)	18 (14.1)			19 (15.4)	18 (14.6)	
Resection							

status

R0	176 (96.7)	125 (97.7)	0.741	0.058	118 (95.9)	120 (97.6)	0.092
R1	6 (3.3)	3 (2.3)			5 (4.1)	3 (2.4)	
Log(CA19-9) (U/mL)	3.49±1.72	3.67±1.71	0.365	0.105	3.67±1.76	3.58±1.64	0.056
CA19-9 (U/mL)							
Normal	109 (59.9)	74 (57.8)	0.714	0.042	67 (54.5)	74 (60.2)	
Elevated	73 (40.1)	54 (42.2)			56 (45.5)	49 (39.8)	

Values are presented as mean±SD or number (%). CA 19-9, carbohydrate antigen 19-9; LVI, lymphovascular invasion; M/D, moderately differentiated; P/D, poorly differentiated; PNI, perineural invasion; W/D, well differentiated. [a]Prosensity score matching was used with 1:1 greedy nearest neighbor algorithm within specified caliper widths, [b]For categorical variables, chi-square test or Fisher exact test was used, and number (%) was reported. For continuous variables, t-test was used, and mean±SD was reported, [c]SMD, standardized difference. SMD < 0.1 is considered as balanced.